Oncology Molecular Diagnostics Market Report 2021

Home   /   Oncology Molecular Diagnostics Market Report 2021

Published Date: August 2021 | Pages: 154 | Category: Pharma and Healthcare | Report Code: GRMI64117

Extract:

 

Based on this comprehensive report published by Gravitas Market Insights, the Oncology Molecular Diagnostics market is said to witness a significant growth during the forecast years between 2021 and 2028. Molecular diagnostic tests look for specific biologic molecules, or biomarkers, in tissue and fluid samples from patients. Based on the characteristics of or changes in the biomarker, molecular diagnostic tests can be used to select a cancer therapy and/or to monitor the effects of a treatment.

 

Report Scope in detail:

 

This latest report edition of Oncology Molecular Diagnostics market has been added to our huge database of detailed reports and this envisions to shape the future of all the related businesses. Our team of learned research analysts have studied in-depth and curated the report based on several aspects which include the overview of the market, driving forces, growth rate, market trends, market size, opportunities and challenges of the market; along with detailed competitive analysis on the regional as well as global level. The Oncology Molecular Diagnostics market research report renders a thorough analysis of the market on a global aspect and aims on several market segmentation. This report also provides deeper perception into the latest trends of the market and pinpoints crucial product developments of the industry. Furthermore, the report collects numerous factors that have accredited to the growth of the market in the recent years.

 

Market Dynamics:

 

  • A significant driver is the growing demand for technologically advanced diagnostics products that are accurate, fast, and cost-effective.
  • Rising patient and healthcare professional awareness of the importance of early cancer detection is expected to increase the use of molecular diagnostic techniques in oncology.
  • India and Australia are expected to have enormous potential for this industry, owing to their growing economies and high unmet needs.
  • Qiagen and Lilly announced plans to collaborate on the development of companion diagnostics for the detection of common cancer biomarkers.

 

Oncology Molecular Diagnostics Market Segmentation:

 

By Product Type

  • Reagents
  • Instrument
  • Others

 

By Technology Type

  • DNA Sequencing and Next-Generation Sequencing
  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Transcription Mediated Amplification (TMA)
  • In-situ Hybridization
  • Mass Spectrometry
  • Chips and Microarrays
  • Others

 

By Application

  • Prostate Cancer
  • Lung Cancer
  • Breast Cancer
  • Liver Cancer
  • Cervical Cancer
  • Blood Cancer
  • Colorectal Cancer
  • Others

 

By End Use

  • Diagnostic Centers
  • Hospitals
  • Others

 

Regional Coverage

 

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Korea
    • Australia
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

 

Competitive Analysis:

 

Eminent market players have been outlined in order to extract improved insights into the worldwide businesses. Our research reports offer all-inclusive information on various top most manufacturers that are operational across global regions. We provide company profiles which include detailed overview of the company, business information, business performance, crucial strategies implemented through the years.

 

Few of the Key Players Covered in Our Report:

 

  • F-Hoffmann La-Roche Ltd
  • BAYER AG
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Danaher Corporation (Cepheid)
  • Veracyte, Inc
  • Siemens Healthineers
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Sysmex Corporation (Sysmex Europe GmbH)
  • TBG Diagnostics Limited

 

Impact of COVID19:

 

The COVID19 pandemic crippled the global economy, it resulted in a worldwide lockdown and this has majorly impacted numerous industries. Our industry experts are working round-the-clock to identify, accumulate and in-time deliver market analysis due to the effect of unprecedented decisions in COVID-19 repercussions on many businesses. The full version of this report will comprise the overall impact of the pandemic, and predicted alteration on the future outlook of the industry, by taking into the account the economic, political, technological and social parameters.

This research study involves broad usage of both secondary and primary data sources. The research process involves the identification of numerous factors which affect the industry, comprising the market environment, government policy, historical data, present trends in the market, competitive landscape, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges.



Market Estimation

Top-down and bottom-up approaches are used for validating the market size for companies, regional segments along with relevant market segmentations such as product type and application.
This report includes market estimations which are based on the marketed sale price of a product. Further breakdown of product segments, particular market share are formed based on the weightage assigned to every segment, which is derived of their usage rate and average price. The entire probable factors which effect the markets and influence them in a great way are included in this research report; and have been accounted for, studied in-depth and are confirmed through primary research. These are then studies to get the final qualitative and quantitative data. Any of the factors such as the outcome of inflation, economic downfall, and any kind of policy and regulatory alterations and/or other such factors are not accounted for in the market forecast. All of this data is amalgamated and included with thorough inputs and analysis from Gravitas Market Insights is curated in this report.



Along with the previously mentioned approaches, various data triangulation methods, in order to conduct market estimations and market forecasting for the complete market segments are detailed in this report. Key Companies present in the said market are also acknowledged via in-depth secondary research and primary research.

Section 1: Executive Summary


1.1. Oncology Molecular Diagnostics Market Industry 360° outline, Year 2016 – 2028
1.2. Business Model Trends
1.3. Growth Trends
1.4. End-User/Technology Type Trends
1.5. Regional Trends


Section 2: Market Dynamics - Oncology Molecular Diagnostics Market Industry Insights


2.1. Growth Drivers
2.2. Opportunities
2.3. Industry challenges
2.4. SWOT Analysis
2.5. Porter’s Analysis
2.6. Worldwide Industry Landscape, Year 2016 – 2028
2.7. Industry Segmentation
2.8. Technology & Invention landscape
2.9. Regional Landscape
2.9.1. North America
2.9.2. Europe
2.9.3. Asia-Pacific
2.9.4. South America
2.9.5. Middle East & Africa
2.10. Competitive Environment


Section 3: Global Oncology Molecular Diagnostics Market, By Product Type


3.1. Segmentation Analysis, By Product Type, 2016-2028
3.2. Market Share Segmentation Analysis, By Product Type, 2016-2028
3.3. Reagents
3.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.4. Instrument
3.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.5. Others
3.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


Section 4: Global Oncology Molecular Diagnostics Market, By Technology Type


4.1. Segmentation Analysis, By Technology Type, 2016-2028
4.2. Market Share Segmentation Analysis, By Technology Type, 2016-2028
4.3. DNA Sequencing and Next-Generation Sequencing
4.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.4. Polymerase Chain Reaction (PCR)
4.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.5. Isothermal Nucleic Acid Amplification Technology (INAAT)
4.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.6. Transcription Mediated Amplification (TMA)
4.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.7. In-situ Hybridization
4.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.8. Mass Spectrometry
4.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.9. Chips and Microarrays
4.9.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.10. Others
4.10.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


Section 5: Global Oncology Molecular Diagnostics Market, By Application


5.1. Segmentation Analysis, By Application, 2016-2028
5.2. Market Share Segmentation Analysis, By Application, 2016-2028
5.3. Prostate Cancer
5.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.4. Lung Cancer
5.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.5. Breast Cancer
5.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.6. Liver Cancer
5.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.7. Cervical Cancer
5.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.8. Blood Cancer
5.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.9. Colorectal Cancer
5.9.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.10. Others
5.10.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


Section 6: Global Oncology Molecular Diagnostics Market, By End Use


6.1. Segmentation Analysis, By End Use, 2016-2028
6.2. Market Share Segmentation Analysis, By End Use, 2016-2028
6.3. Diagnostic Centers
6.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4. Hospitals
6.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.5. Others
6.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


Section 7: Global Oncology Molecular Diagnostics Market, Regional Analysis


7.1. Global Oncology Molecular Diagnostics Market, Regional Analysis


7.2. North America, Country level Analysis
7.2.1. North America Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Product Type, 2016 – 2028
7.2.2. North America Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Technology Type, 2016 – 2028
7.2.3. North America Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Application, 2016 – 2028
7.2.4. North America Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By End Use, 2016 – 2028
7.2.5. United States
7.2.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.2.6. Canada
7.2.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.2.7. Mexico
7.2.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


7.3. Europe Country level Analysis
7.3.1. Europe Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Product Type, 2016 – 2028
7.3.2. Europe Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Technology Type, 2016 – 2028
7.3.3. Europe Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Application, 2016 – 2028
7.3.4. Europe Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By End Use, 2016 – 2028
7.3.5. UK
7.3.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.6. Germany
7.3.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.7. France
7.3.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.8. Italy
7.3.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.9. Spain
7.3.9.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.10. Russia
7.3.10.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.11. Rest of Europe
7.3.11.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


7.4. Asia-Pacific Country level Analysis
7.4.1. Asia-Pacific Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Product Type, 2016 – 2028
7.4.2. Asia-Pacific Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Technology Type, 2016 – 2028
7.4.3. Asia-Pacific Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Application, 2016 – 2028
7.4.4. Asia-Pacific Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By End Use, 2016 – 2028
7.4.5. China
7.4.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.6. India
7.4.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.7. Japan
7.4.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.8. Korea
7.4.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.9. Australia
7.4.9.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.10. Southeast Asia
7.4.10.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.11. Rest of Asia-Pacific
7.4.11.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


7.5. South America Country level Analysis
7.5.1. South America Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Product Type, 2016 – 2028
7.5.2. South America Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Technology Type, 2016 – 2028
7.5.3. South America Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Application, 2016 – 2028
7.5.4. South America Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By End Use, 2016 – 2028
7.5.5. Brazil
7.5.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.5.6. Argentina
7.5.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.5.7. Colombia
7.5.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.5.8. Rest of South America
7.5.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


7.6. Middle East & Africa Country level Analysis
7.6.1. MEA Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Product Type, 2016 – 2028
7.6.2. MEA Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Technology Type, 2016 – 2028
7.6.3. MEA Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By Application, 2016 – 2028
7.6.4. MEA Oncology Molecular Diagnostics Market estimates and forecast with Growth rate analysis, By End Use, 2016 – 2028
7.6.5. GCC
7.6.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.6.6. South Africa
7.6.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.6.7. Rest of Middle East & Africa
7.6.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


Section 8: Company Profile - Oncology Molecular Diagnostics Market


8.1. F-Hoffmann La-Roche Ltd
8.1.1. Business Overview
8.1.2. Product & Service Offering
8.1.3. Overall Revenue
8.1.4. Strategic Outlook


8.2. BAYER AG
8.2.1. Business Overview
8.2.2. Product & Service Offering
8.2.3. Overall Revenue
8.2.4. Strategic Outlook


8.3. Abbott Laboratories
8.3.1. Business Overview
8.3.2. Product & Service Offering
8.3.3. Overall Revenue
8.3.4. Strategic Outlook


8.4. Becton, Dickinson and Company
8.4.1. Business Overview
8.4.2. Product & Service Offering
8.4.3. Overall Revenue
8.4.4. Strategic Outlook


8.5. Danaher Corporation (Cepheid)
8.5.1. Business Overview
8.5.2. Product & Service Offering
8.5.3. Overall Revenue
8.5.4. Strategic Outlook


8.6. Veracyte, Inc
8.6.1. Business Overview
8.6.2. Product & Service Offering
8.6.3. Overall Revenue
8.6.4. Strategic Outlook


8.7. Siemens Healthineers
8.7.1. Business Overview
8.7.2. Product & Service Offering
8.7.3. Overall Revenue
8.7.4. Strategic Outlook


8.8. QIAGEN
8.8.1. Business Overview
8.8.2. Product & Service Offering
8.8.3. Overall Revenue
8.8.4. Strategic Outlook


8.9. Thermo Fisher Scientific Inc.
8.9.1. Business Overview
8.9.2. Product & Service Offering
8.9.3. Overall Revenue
8.9.4. Strategic Outlook


8.10. Illumina, Inc.
8.10.1. Business Overview
8.10.2. Product & Service Offering 
8.10.3. Overall Revenue
8.10.4. Strategic Outlook


8.11. Sysmex Corporation (Sysmex Europe GmbH)
8.11.1. Business Overview
8.11.2. Product & Service Offering
8.11.3. Overall Revenue
8.11.4. Strategic Outlook


8.12. TBG Diagnostics Limited
8.12.1. Business Overview
8.12.2. Product & Service Offering
8.12.3. Overall Revenue
8.12.4. Strategic Outlook


8.13. bioMérieux SA
8.13.1. Business Overview
8.13.2. Product & Service Offering 
8.13.3. Overall Revenue
8.13.4. Strategic Outlook

 

*Market size and forecast will be provided from 2016-2028, and forecast period would be 2021-2028
*Details on financial performance and strategic moves and developments may not be captured for unlisted companies
*List of companies profiled in this TOC is tentative and may change after detailed analysis